8-K: Vivos Therapeutics Faces Nasdaq Delisting Risk Despite Recent Capital Raise

Vivos Therapeutics is facing potential delisting from Nasdaq due to failing to meet minimum stockholders' equity requirements, despite a recent $7.5 million private placement.

Summary

• Vivos Therapeutics received a notice from Nasdaq on May 16, 2024, stating they did not meet the minimum stockholders' equity requirement of $2.5 million as of March 31, 2024.
• The company completed a $7.5 million private placement on June 10, 2024, and believes they now meet the equity requirement.
• A hearing with a Nasdaq Hearings Panel is scheduled for June 27, 2024, where Vivos will argue for continued listing.
• The panel's decision is expected within 30 days of the hearing.
• Failure to maintain compliance could result in delisting from Nasdaq, which would negatively impact the company's stock price, ability to raise capital, and overall reputation.
• Vivos anticipates needing to raise additional equity capital to ensure ongoing compliance with the equity requirement.

Sentiment

Score: 3

Explanation: The document highlights significant risks and uncertainties regarding the company's future, particularly the potential for delisting. While a recent capital raise is positive, the need for further capital and the pending hearing create a negative outlook.

Positives

• The company completed a $7.5 million private placement which they believe has restored compliance with the minimum stockholders' equity requirement.

Negatives

• The company received a delisting notice from Nasdaq due to not meeting the minimum stockholders' equity requirement.
• There is a risk that the company will be unable to raise sufficient capital to demonstrate ongoing compliance.
• Delisting from Nasdaq could have a material adverse effect on the company's stock price, ability to raise capital, and overall reputation.

Risks

• The company faces the risk of delisting from Nasdaq if they cannot maintain compliance with the minimum stockholders' equity requirement.
• There is a risk that the company will be unable to raise sufficient capital to demonstrate ongoing compliance.
• Delisting could negatively impact the company's stock price, ability to raise capital, and overall reputation.

Future Outlook

The company anticipates needing to raise additional equity capital to ensure ongoing compliance with the equity requirement and faces the risk of delisting if they cannot maintain compliance.

Management Comments

• The company believes it has stockholders' equity of at least $2.5 million as of the date of the filing of this Current Report on Form 8-K.
• The company plans to address its past, current, and anticipated future compliance with the Equity Requirement at the hearing.
• The company anticipates receipt of the Panel's decision within 30 days of the hearing.

Industry Context

This situation highlights the challenges faced by smaller companies in maintaining listing requirements, especially in volatile market conditions. It is not uncommon for companies to face delisting notices due to financial difficulties.

Comparison to Industry Standards

• Many small-cap and micro-cap companies struggle to maintain Nasdaq listing requirements, particularly the minimum stockholders' equity rule.
• Companies like Vivos often rely on private placements or other forms of capital raising to meet these requirements.
• The risk of delisting is a common concern for companies with volatile stock prices or limited access to capital.
• Other companies in the medical device or biotech space have faced similar challenges, such as [Company A] which was delisted in [Year] due to similar issues, and [Company B] which successfully raised capital to avoid delisting in [Year].

Stakeholder Impact

• Shareholders face the risk of a significant drop in stock price and reduced liquidity if the company is delisted.
• The company's ability to raise capital could be severely impacted by a delisting.
• The company's reputation could be damaged by a delisting, potentially affecting future business opportunities.

Next Steps

• The company will attend a hearing with the Nasdaq Hearings Panel on June 27, 2024.
• The company anticipates receiving the Panel's decision within 30 days of the hearing.
• The company will likely need to raise additional equity capital to maintain compliance with Nasdaq listing requirements.

Key Dates

Keywords

Nasdaq, delisting, stockholders' equity, compliance, private placement, capital raise, hearing